4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    65.
    发明申请
    4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION 有权
    4-DIARYLAMINOTHIAZINES作为BACE1抑制剂及其用于减少β-淀粉样生成的用途

    公开(公告)号:US20150329506A1

    公开(公告)日:2015-11-19

    申请号:US14653025

    申请日:2012-12-19

    摘要: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or —CH3; or R1 and R2 can join together in a ring by adding —(CH2)4—; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, —C═OC1-4 alkyl, —SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is —NHCO—, or is a single bond; and L and Z together can be absent.

    摘要翻译: 包括其药学上可接受的盐的式(I)化合物在本文中阐述:(I)其中R 1和R 2独立地是氢或-CH 3; 或者R 1和R 2可以通过加入 - (CH 2)4 - R3是氢或C1-C3烷基; Y和Z独立地是C 6 -C 10 - 芳基或5-10元杂环基,其可以进一步被0-3个选自以下的取代基取代:卤素,羟基,氨基,C 1-4烷基氨基,C 1-4二烷基氨基 卤代C 1-4烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基,-C 1 -C 1-4烷基,-SO 2 C 1-4烷基和C 2 -C 4炔基; A选自苯基,苄基,恶唑基,噻唑基,异恶唑基,咪唑基,吡唑基,吡啶基,嘧啶基和吡嗪基,其可以进一步被0-3个选自以下的取代基取代:卤素,羟基,氨基, C 1-4烷基氨基,C 1-4二烷基氨基,卤代C 1-4烷基,羟基C 1-6烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基和C 2 -C 4炔基; L是-NHCO-,或是单键; 可以不存在L和Z。

    AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP
    68.
    发明申请
    AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP 审中-公开
    取代周期集团的氨基二氢卟酚衍生物

    公开(公告)号:US20140073815A1

    公开(公告)日:2014-03-13

    申请号:US13887745

    申请日:2013-05-06

    IPC分类号: C07C215/20

    摘要: This invention provides a compound of the formula (I): wherein the ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 is optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl; R2a and R2b are each independently hydrogen, optionally substituted lower alkyl or optionally substituted acyl; R3a, R3b, R3c and R3d are each independently hydrogen, halogen, hydroxy or optionally substituted lower alkyl etc.; a pharmaceutically acceptable salt or solvate thereof, which is useful for treating diseases induced by production, secretion and/or deposition of amyloid β protein.

    摘要翻译: 本发明提供式(I)的化合物:其中环A是任选取代的碳环基或任选取代的杂环基; R1是任选取代的低级烷基,任选取代的低级烯基,任选取代的低级炔基; R2a和R2b各自独立地为氢,任选取代的低级烷基或任选取代的酰基; R3a,R3b,R3c和R3d各自独立地为氢,卤素,羟基或任选取代的低级烷基等; 其药学上可接受的盐或溶剂合物,其可用于治疗由淀粉样β蛋白的产生,分泌和/或沉积诱导的疾病。